Cite
Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
MLA
Ramachandra, Chrishan J. A., et al. “Inhibiting Cardiac Myeloperoxidase Alleviates the Relaxation Defect in Hypertrophic Cardiomyocytes.” Cardiovascular Research, vol. 118, no. 2, Jan. 2022, pp. 517–30. EBSCOhost, https://doi.org/10.1093/cvr/cvab077.
APA
Ramachandra, C. J. A., Kp, M. M. J., Chua, J., Hernandez-Resendiz, S., Liehn, E. A., Knöll, R., Gan, L.-M., Michaëlsson, E., Jonsson, M. K. B., Ryden-Markinhuhta, K., Bhat, R. V., Fritsche-Danielson, R., Lin, Y.-H., Sadayappan, S., Tang, H. C., Wong, P., Shim, W., & Hausenloy, D. J. (2022). Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes. Cardiovascular Research, 118(2), 517–530. https://doi.org/10.1093/cvr/cvab077
Chicago
Ramachandra, Chrishan J A, Myu Mai Ja Kp, Jasper Chua, Sauri Hernandez-Resendiz, Elisa A Liehn, Ralph Knöll, Li-Ming Gan, et al. 2022. “Inhibiting Cardiac Myeloperoxidase Alleviates the Relaxation Defect in Hypertrophic Cardiomyocytes.” Cardiovascular Research 118 (2): 517–30. doi:10.1093/cvr/cvab077.